• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

    5/7/24 4:01:00 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRS alert in real time by email

    - Progressing ATI-2138 into Atopic Dermatitis -

    - Management to Host Conference Call at 5:00 PM ET Today -

    WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a corporate update.

    "We are pleased to announce that following a review of the potential development pathways for ATI-2138, our investigational ITK/JAK3 compound with best-in-class potential, we have decided to progress ATI-2138 into a proof-of-concept Phase 2a trial in patients with moderate to severe atopic dermatitis," stated Dr. Neal Walker, co-founder and Interim Chief Executive Officer & President of Aclaris. "Across all of our programs, we remain focused on executing a capital efficient strategy to advance novel immuno-inflammatory therapies."

    Research and Development Highlights:

    • ITK Inhibitor Programs
      • ATI-2138, an investigational oral covalent ITK/JAK3 inhibitor
        • Aclaris plans to progress ATI-2138 into a Phase 2a trial in subjects with moderate to severe atopic dermatitis.
        • In September 2023, Aclaris reported positive results from its Phase 1 multiple ascending dose (MAD) trial of ATI-2138.
      • ITK Selective Compound
        • Aclaris is progressing to development candidate selection a second generation ITK selective inhibitor for autoimmune indications.
    • Lepzacitinib (ATI-1777), an investigational topical "soft" JAK 1/3 inhibitor
      • In January 2024, Aclaris reported positive top-line results from its Phase 2b trial in atopic dermatitis (AD).
      • Aclaris is currently seeking a global development and commercialization partner for this program (excluding Greater China). As previously announced, in 2022 Aclaris granted Pediatrix Therapeutics exclusive rights to develop and commercialize lepzacitinib in Greater China.

    • Zunsemetinib (ATI-450), an investigational oral small molecule MK2 inhibitor

      • Aclaris plans to support Washington University in St. Louis in its investigator-initiated Phase 1b/2 trials of zunsemetinib as a potential treatment for pancreatic cancer and metastatic breast cancer. Aclaris expects these trials to be primarily funded by grants awarded to Washington University.

    Financial Highlights:

    Liquidity and Capital Resources

    As of March 31, 2024, Aclaris had aggregate cash, cash equivalents and marketable securities of $161.4 million compared to $181.9 million as of December 31, 2023. A majority of cash expenditures in the first quarter of 2024 were related to payments associated with exit activities, including the wind down of discontinued R&D programs and the previously announced reduction in force. Aclaris anticipates payments associated with these activities to be substantially completed by the second quarter of 2024. As a result, Aclaris expects significantly lower quarterly cash expenditures in future quarters, without giving effect to any potential business development activities resulting from its ongoing strategic review of its business.

    Financial Results

    First Quarter 2024

    • Net loss was $16.9 million for the first quarter of 2024 compared to $28.2 million for the first quarter of 2023.

    • Total revenue was $2.4 million for the first quarter of 2024 compared to $2.5 million for the first quarter of 2023. The decrease was primarily driven by lower contract research revenue during the three months ended March 31, 2024.

    • Research and development (R&D) expenses were $9.8 million for the quarter ended March 31, 2024 compared to $22.6 million for the prior year period.



      • The $12.8 million decrease was primarily the result of lower:
        • Zunsemetinib development expenses associated with clinical activities for a Phase 2a trial for hidradenitis suppurativa, a Phase 2b trial for rheumatoid arthritis, and drug candidate manufacturing costs.
        • Costs associated with lepzacitinib preclinical development activities and a Phase 2b clinical trial for AD.
        • ATI-2138 development expenses, including costs associated with a Phase 1 MAD trial and other preclinical activities.
        • Compensation-related expenses due to a decrease in headcount and higher forfeiture credits.
    • General and administrative (G&A) expenses were $6.8 million for the quarter ended March 31, 2024 compared to $8.8 million for the prior year period. The decrease was primarily due to a reduction in compensation-related expenses due to lower headcount and higher forfeiture credits.

    • Licensing expenses were $1.0 million for the quarter ended March 31, 2024 compared to $1.1 million for the prior year period. The decrease was due to the achievement of a commercial milestone during the three months ended March 31, 2023, offset by an increase in royalties earned under the Lilly license agreement.

    • Revaluation of contingent consideration resulted in a $2.8 million loss for the quarter ended March 31, 2024 compared to a gain of $0.8 million for the prior year period.

    Conference Call and Webcast

    As previously disclosed on April 30, 2024, management will host a conference call and webcast, with an accompanying slide presentation, at 5:00 PM ET today to provide a corporate update. To access the live webcast of the call and the accompanying slide presentation, please visit the "Events" page of the "Investors" section of Aclaris' website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.

    About Aclaris Therapeutics, Inc.

    Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

    Cautionary Note Regarding Forward-Looking Statements

    Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "anticipate," "believe," "expect," "intend," "may," "plan," "potential," "will," and similar expressions, and are based on Aclaris' current beliefs and expectations. These forward-looking statements include expectations regarding its plans for its development programs, including its plans to seek a development and commercialization partner for lepzacitinib, the clinical development of ATI-2138, and its plan to support Washington University in St. Louis in its investigator-initiated Phase 1b/2 trials of zunsemetinib, as well as Aclaris' expectations regarding the wind down of discontinued R&D programs and costs associated with its recent reduction in force and the associated impact on anticipated cash burn, and its strategic review of its business. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris' reliance on third parties over which it may not always have full control, Aclaris' ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of Aclaris' Annual Report on Form 10-K for the year ended December 31, 2023, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the "SEC Filings" page of the "Investors" section of Aclaris' website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

     
    Aclaris Therapeutics, Inc.

    Condensed Consolidated Statements of Operations

    (unaudited, in thousands, except share and per share data)
     
      Three Months Ended
      March 31,
      2024     2023 
    Revenues:      
    Contract research $657  $889 
    Licensing  1,741   1,639 
    Total revenue  2,398   2,528 
           
    Costs and expenses:      
    Cost of revenue (1)  809   808 
    Research and development (1)  9,845   22,587 
    General and administrative (1)  6,844   8,790 
    Licensing  1,031   1,061 
    Revaluation of contingent consideration  2,800   (800)
    Total costs and expenses  21,329   32,446 
    Loss from operations  (18,931)  (29,918)
    Other income, net  1,990   1,758 
    Net loss $(16,941) $(28,160)
    Net loss per share, basic and diluted $(0.24) $(0.42)
    Weighted average common shares outstanding, basic and diluted  71,074,858   66,872,778 
           
    (1) Amounts include stock-based compensation expense as follows:      
           
    Cost of revenue $252  $299 
    Research and development  (29)  2,602 
    General and administrative  1,866   3,905 
    Total stock-based compensation expense $2,089  $6,806 



     
    Aclaris Therapeutics, Inc.

    Selected Consolidated Balance Sheet Data

    (unaudited, in thousands, except share data)
     
      March 31, 2024 December 31, 2023
             
    Cash, cash equivalents and marketable securities $161,365  $181,877 
    Total assets $174,065  $197,405 
    Total current liabilities $20,080  $30,952 
    Total liabilities $32,051  $40,226 
    Total stockholders' equity $142,014  $157,179 
    Common stock outstanding  71,248,017   70,894,889 



     
    Aclaris Therapeutics, Inc.

    Selected Consolidated Cash Flow Data

    (unaudited, in thousands)
     
      March 31, 2024 March 31, 2023
           
    Net loss $(16,941) $(28,160)
    Depreciation and amortization  243   198 
    Stock-based compensation expense  2,089   6,806 
    Revaluation of contingent consideration  2,800   (800)
    Changes in operating assets and liabilities  (9,006)  (4,397)
    Net cash used in operating activities $(20,815) $(26,353)



    Aclaris Therapeutics Contact:

    [email protected]

     



    Primary Logo

    Get the next $ACRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACRS

    DatePrice TargetRatingAnalyst
    3/18/2025Overweight
    Cantor Fitzgerald
    12/23/2024$20.00Neutral → Buy
    H.C. Wainwright
    11/20/2024Neutral → Overweight
    Cantor Fitzgerald
    11/19/2024$2.00 → $7.00Market Perform → Outperform
    Leerink Partners
    11/19/2024$8.00Neutral → Buy
    BTIG Research
    11/19/2024$2.00 → $7.00Hold → Buy
    Jefferies
    11/18/2024$3.00 → $13.00Neutral → Overweight
    Piper Sandler
    1/22/2024Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $ACRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aclaris Therapeutics to Participate in the HC Wainwright "HCW@Home" Series

      WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris' Chief Executive Officer Neal Walker and other members of the Aclaris senior leadership team will participate in a fireside chat during the virtual HC Wainwright "HCW@Home" series. The virtual fireside chat will take place on Friday May 16, 2025, at 1:00 PM EDT. A live and archived webcast of the event will be accessible on the Events page of https://www.aclaristx.com/. The webcast will be available on the Aclaris website for at least 30 days. About Ac

      5/9/25 7:00:19 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      - Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships - - Investigational New Drug (IND) Application for Bispecific Antibody ATI-052 Cleared by U.S. Food and Drug Administration - WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial res

      5/8/25 6:50:51 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

      WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has been appointed as Chief Medical Officer. Dr. Hall's extensive medical and clinical development experience in areas including immunology and antibody development will be essential as he leads Aclaris' clinical strategy to fully leverage the opportunities in the Company's portfolio of immuno-inflammatory product candidates. "At Aclaris, our vision is to drive the leading edge of therapeutic innovation in I&I; Jesse shares this vision and

      4/29/25 7:00:32 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mehra Anand bought $1,499,998 worth of shares (666,666 units at $2.25), increasing direct ownership by 1,537% to 710,030 units (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      11/20/24 4:20:04 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Leonard Braden Michael bought $472,757 worth of shares (373,569 units at $1.27) (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      8/5/24 3:57:34 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Leonard Braden Michael bought $359,010 worth of shares (273,730 units at $1.31) (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      7/31/24 4:10:09 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Aclaris Therapeutics

      Cantor Fitzgerald resumed coverage of Aclaris Therapeutics with a rating of Overweight

      3/18/25 8:23:58 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Aclaris Therapeutics from Neutral to Buy and set a new price target of $20.00

      12/23/24 7:21:33 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Aclaris Therapeutics from Neutral to Overweight

      11/20/24 3:46:36 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Hall Jesse Wayne

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      5/5/25 4:32:56 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Hall Jesse Wayne

      3 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      5/5/25 4:29:44 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Walker Neal converted options into 9,467 shares and covered exercise/tax liability with 2,975 shares, increasing direct ownership by 0.44% to 1,479,824 units (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      5/5/25 4:20:04 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Leadership Updates

    Live Leadership Updates

    See more
    • Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

      WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has been appointed as Chief Medical Officer. Dr. Hall's extensive medical and clinical development experience in areas including immunology and antibody development will be essential as he leads Aclaris' clinical strategy to fully leverage the opportunities in the Company's portfolio of immuno-inflammatory product candidates. "At Aclaris, our vision is to drive the leading edge of therapeutic innovation in I&I; Jesse shares this vision and

      4/29/25 7:00:32 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

      CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will continue to serve as Chair of the Company's Board of Directors.

      4/23/24 8:00:00 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Announces Key Leadership Transitions

      - Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr. Walker as Chief Executive Officer and appointed to the Board of Directors - Kevin Balthaser appointed Chief Financial Officer to succeed retiring Frank Ruffo - Matthew Rothman appointed General Counsel WAYNE, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced several key leadership changes. Effective January 1, 2023, co-founder

      11/22/22 4:01:00 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Aclaris Therapeutics Inc.

      10-Q - Aclaris Therapeutics, Inc. (0001557746) (Filer)

      5/8/25 4:30:29 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)

      5/8/25 7:15:40 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Aclaris Therapeutics Inc.

      SCHEDULE 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

      5/5/25 4:00:33 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Aclaris Therapeutics Inc.

      SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

      11/25/24 11:02:19 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aclaris Therapeutics Inc.

      SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

      11/22/24 4:00:23 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aclaris Therapeutics Inc.

      SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

      11/21/24 4:51:50 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Financials

    Live finance-specific insights

    See more
    • Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      - Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships - - Investigational New Drug (IND) Application for Bispecific Antibody ATI-052 Cleared by U.S. Food and Drug Administration - WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial res

      5/8/25 6:50:51 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

      - Rich Catalyst Calendar Expected in 2025 Including Phase 2 Data in Multiple Immuno-Inflammatory Disease Indications - - Data from CTTQ's Phase 2 Studies of Bosakitug (ATI-045) in Chinese Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Expected in the First Half of 2025 to Inform Internal Development Programs - - Initiation of Enrollment in Phase 2b Trial for Bosakitug in Atopic Dermatitis (AD) on Track for the First Half of 2025 - - Cash Runway Expected into 2028 - WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inf

      2/27/25 6:59:55 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

      - Enhances Aclaris' pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) --  Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into an exclusive license agreement with Biosion, Inc. (Biosion) for worldwide rights (excluding Greater China) to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-cl

      11/18/24 8:10:04 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care